Biomea Fusion (BMEA) Stock Jumps on Durable Diabetes Drug Data: Outlook, Analyst Targets and Key Risks as of December 5, 2025
Biomea Fusion, Inc. (NASDAQ: BMEA) is back in the spotlight after the company reported long‑term data showing that its experimental diabetes drug icovamenib (formerly BMF‑219) can deliver durable blood‑sugar control many months after patients stop taking it. The new results,